MTInov

MTInov : Large scale human and mammalian cell production

The MTInov Biotherapy-Bioproduction Integrator was created in 2020 by the collaboration between the Cell Therapy and Tissue Banking Unit (UTCT) of the Nancy CHRU and the Reactions and Process Engineering Laboratory. This structure, dedicated to research into advanced therapy medicinal products (ITMs), was set up following a call for projects launched as part of the Grand Défi biomédicament, and was then accredited as a Biotherapy Bioproduction Integrator in 2022 as part of the France 2030 Acceleration Strategy.

This ‘Biotherapy-Bioproduction Integrator’ accreditation is a key element in innovation in the production of biotherapies. The mission of the integrators is to support the development of innovative technologies for the production of biomedicines by offering skills, equipment and an environment conducive to research, while facilitating collaboration between manufacturers, researchers and start-ups. The aim? To ensure the development and large-scale production of biomedicines, while reducing production costs and helping to relocate production to France.

MTInov is a platform for studying, optimising and scaling up the production of cell-based biomedicines, with expertise in cell culture in stirred bioreactors (kinetic monitoring, intensification, modelling, bioreactor conception and design), as well as in the transfer to clinical grade in compliance with good manufacturing practice (GMP).

In this way, the UTCT and LRGP teams form a multidisciplinary partnership with complementary activities concerning both biotherapies and the development of bioprocesses to improve the yields and quality of cellular or cell-based products.

To find out more, visit the MTInov website : https://mtinov.cnrs.fr/

5

UTCT hospital-academics

8

Hospital technicians

1

Clinical research technician

7

Researchers and teacher-researchers

4

Engineers and technicians

Key figures

Since its creation, 15 fixed-term contracts have been financed on MTInov projects (post-docs, design engineers, technicians, sandwich students), including one business development post, financed directly by IBB.

Fields of expertise

  • Clinical-grade production of cell therapy products in compliance with Good Tissue and Cell Practices (GTCP)
  • Clinical-grade production of advanced therapy drugs (ITM-Punctually Prepared and ITM-Experimental, within the framework of clinical trials) in compliance with Good Pharmaceutical Manufacturing Practices (GMP).
  • Quality control of cellular products, including functional products.
  • Process development for the production of experimental ITMs.
  • Process engineering for human and animal cell culture in bioreactors.
  • On-line monitoring and control of bioreactor cultures.
  • Kinetic modeling, bioreactor extrapolation.
  • Numerical simulation of flows in cell culture bioreactors and bioreactor design.
  • Multi-scale modeling of interactions between MSCs and their culture media.

* Integrator Biotherapy Biomedicine